709
Participants
Start Date
December 31, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
Desvenlafaxine Succinate Sustained-Release (DVS SR)
25 mg tablet, once daily dosing for 8 weeks
Desvenlafaxine Succinate Sustained-Release (DVS SR)
50 mg tablet, once daily dosing for 8 weeks
placebo
Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Pfizer Investigational Site, Columbia
Pfizer Investigational Site, Smyrna
Pfizer Investigational Site, Atlanta
Pfizer Investigational Site, St. Petersburg
Pfizer Investigational Site, Memphis
Pfizer Investigational Site, Dayton
Pfizer Investigational Site, Brown Deer
Pfizer Investigational Site, Libertyville
Pfizer Investigational Site, Dallas
Pfizer Investigational Site, San Antonio
Pfizer Investigational Site, Salt Lake City
Pfizer Investigational Site, Beverly Hills
Pfizer Investigational Site, Cerritos
Pfizer Investigational Site, Los Alamitos
Pfizer Investigational Site, Arcadia
Pfizer Investigational Site, Garden Grove
Pfizer Investigational Site, Kirkland
Pfizer Investigational Site, Seattle
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Chiyoda City
Pfizer Investigational Site, Chiyoda City
Pfizer Investigational Site, Minato
Pfizer Investigational Site, Taitō City
Pfizer Investigational Site, Bunkyo
Pfizer Investigational Site, Katsushika-ku
Pfizer Investigational Site, Shinagawa
Pfizer Investigational Site, Shinagawa
Pfizer Investigational Site, Shinagawa
Pfizer Investigational Site, Shibuya City
Pfizer Investigational Site, Shibuya City
Pfizer Investigational Site, Meguro City
Pfizer Investigational Site, Setagaya-ku
Pfizer Investigational Site, Setagaya City
Pfizer Investigational Site, Shinjyuku
Pfizer Investigational Site, Nakano City
Pfizer Investigational Site, Suginami
Pfizer Investigational Site, Toshima City
Pfizer Investigational Site, tabashi City
Pfizer Investigational Site, Kodaira
Pfizer Investigational Site, Yokohama
Pfizer Investigational Site, Yokohama
Pfizer Investigational Site, Yokohama
Pfizer Investigational Site, Minamiashigara
Pfizer Investigational Site, Noda
Pfizer Investigational Site, Saitama
Pfizer Investigational Site, Misato, Saitama
Pfizer Investigational Site, Kumagaya
Pfizer Investigational Site, Fujioka
Pfizer Investigational Site, Matsumoto
Pfizer Investigational Site, Nagoya
Pfizer Investigational Site, Toyoake
Pfizer Investigational Site, Kusatsu
Pfizer Investigational Site, Osaka
Pfizer Investigational Site, Sakai
Pfizer Investigational Site, Kyoto
Pfizer Investigational Site, Kobe
Pfizer Investigational Site, Hiroshima
Pfizer Investigational Site, Kure
Pfizer Investigational Site, Hatsukaichi
Pfizer Investigational Site, Ube
Pfizer Investigational Site, Kitakyushu
Pfizer Investigational Site, Kitakyushu
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Fukuoka
Pfizer Investigational Site, Kanzaka
Pfizer Investigational Site, Kumamoto
Pfizer Investigational Site, Kumamoto
Pfizer Investigational Site, Yatsushiro
Pfizer Investigational Site, Kanazawa
Pfizer Investigational Site, Fukushima
Pfizer Investigational Site, Shirakawa
Pfizer Investigational Site, Saitama
Pfizer Investigational Site, East Providence
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Sapporo
Pfizer Investigational Site, Sapporo
Lead Sponsor
Pfizer
INDUSTRY